CA 27-29 in patients with breast cancer with pulmonary fibrosis

$ 14.00

4.9 (649) In stock

A series of 4 patients with breast cancer who have persistent elevation in CA 27.29 are reported, finding that false-positive results might be observed in certain patients with no evidence of malignant disease, such as benign breast disease, ovarian cysts, and liver disease. Cancer antigen (CA) 27-29, which is expressed on most carcinoma cells, is a soluble form of glycoprotein MUC1. It is overexpressed in tumors involving glandular epithelial cells, such as breast tumors. Measurement of CA 27-29 has been approved by the US Food and Drug Administration for monitoring disease activity in patients with breast cancer. Although serial determination of tumor markers after primary treatment for breast cancer can preclinically detect recurrent/metastatic disease with lead times of approximately 2-9 months, the clinical value of this lead time remains to be determined. False-positive results might be observed in certain patients with no evidence of malignant disease, such as benign breast disease, ovarian cysts, and liver disease. Herein, we report a series of 4 patients with breast cancer (2 patients with interstitial lung fibrosis and 2 patients with nonspecific fibrotic lung changes) who have persistent elevation in CA 27.29 (normal, <38 U/mL).

PDF) CA 27-29 in Patients with Breast Cancer with Pulmonary Fibrosis

Pneumonitis and pulmonary fibrosis associated with breast cancer treatments - Document - Gale Academic OneFile

Tumor Markers for Breast Cancer: Benefits, Drawbacks, Results & More

CA 27-29 in Patients with Breast Cancer with Pulmonary Fibrosis

Table 2 from Serum tumor markers in breast cancer: are they of clinical value?

Lung Cancer with Skin and Breast Metastasis: A Case Report and Literature Review

Cureus, Dosimetric Planning Comparison for Left-Sided Breast Cancer Radiotherapy: The Clinical Feasibility of Four-Dimensional-Computed Tomography-Based Treatment Planning Optimization

PDF] Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer.

Dr. Maurice R. Grant, MD, Morgantown, WV, Pathologist

CA27.29: A valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases